Literature DB >> 2308896

Bioavailability improvement of mycophenolic acid through amino ester derivatization.

W A Lee1, L Gu, A R Miksztal, N Chu, K Leung, P H Nelson.   

Abstract

The potential bioavailability improvement of mycophenolic acid (MPA), 1, through ester derivatization was evaluated in monkeys at a dose of 20 mg/kg in this study. The acetyl solketal ester 3 was found to have excellent partition properties but poor aqueous solubility. Thus, even though it can be converted rapidly to MPA by plasma and liver enzymes, it showed poor oral bioavailability (56% of MPA) in monkeys. The bioavailability of the morpholinoethyl ester 4 and the acetyl morpholinoethyl ester 5, on the other hand, was found to be 236 and 150% that of MPA, respectively. Since ester 5 has greater aqueous solubility, but similar chemical stability and enzymatic hydrolysis rates compared to ester 4, the better bioavailability of ester 4 may result from its greater partitioning into the gastrointestinal membranes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2308896     DOI: 10.1023/a:1015828802490

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  Antitumor and immunosuppressive effects of mycophenolic acid derivatives.

Authors:  Y Ohsugi; S Suzuki; Y Takagaki
Journal:  Cancer Res       Date:  1976-08       Impact factor: 12.701

2.  The metabolism and binding of ( 14 C)mycophenolic acid in the rat.

Authors:  R Nery; E Nice
Journal:  J Pharm Pharmacol       Date:  1971-11       Impact factor: 3.765

3.  Preparation and antitumor properties of analogs and derivatives of mycophenolic acid.

Authors:  D F Jones; S D Mills
Journal:  J Med Chem       Date:  1971-04       Impact factor: 7.446

4.  Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals.

Authors:  Y Matsuzawa; T Nakase
Journal:  J Pharmacobiodyn       Date:  1984-10

5.  Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects.

Authors:  R Runkel; M Chaplin; G Boost; E Segre; E Forchielli
Journal:  J Pharm Sci       Date:  1972-05       Impact factor: 3.534

6.  Metabolism and biochemistry of mycophenolic acid.

Authors:  M J Sweeney; D H Hoffman; M A Esterman
Journal:  Cancer Res       Date:  1972-09       Impact factor: 12.701

7.  Antitumor activity of a new compound, ethyl O-[N-(p-carboxyphenyl)-carbamoyl]-mycophenolate, against various experimental tumors upon oral administration.

Authors:  H Mitsui; T Matsuno; H Ogawa; T Shiio; Y Yugari; G Tamura
Journal:  Gan       Date:  1981-02

8.  Preformulation salt selection. Physical property comparisons of the tris(hydroxymethyl)aminomethane (THAM) salts of four analgesic/antiinflammatory agents with the sodium salts and the free acids.

Authors:  L Gu; R G Strickley
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

9.  Simple procedure for determining octanol--aqueous partition, distribution, and ionization coefficients by reversed-phase high-pressure liquid chromatography.

Authors:  S H Unger; J R Cook; J S Hollenberg
Journal:  J Pharm Sci       Date:  1978-10       Impact factor: 3.534

10.  IMP dehydrogenase from the intracellular parasitic protozoan Eimeria tenella and its inhibition by mycophenolic acid.

Authors:  D J Hupe; B A Azzolina; N D Behrens
Journal:  J Biol Chem       Date:  1986-06-25       Impact factor: 5.157

View more
  29 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.

Authors:  A Bianchi-Smiraglia; J A Wawrzyniak; A Bagati; E K Marvin; J Ackroyd; S Moparthy; W Bshara; E E Fink; C E Foley; G E Morozevich; A E Berman; D S Shewach; M A Nikiforov
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

3.  Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.

Authors:  Oliver Lenz; Alessia Fornoni; Gabriel Contreras
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room.

Authors:  Hyunhee Park
Journal:  J Clin Aesthet Dermatol       Date:  2011-01

5.  Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice.

Authors:  C A Jonsson; H Carlsten
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

Review 6.  The role of mycophenolate mofetil in clinical renal transplantation.

Authors:  E E Hodge
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

7.  A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.

Authors:  Chie Onishi; Kazuteru Ohashi; Takeshi Sawada; Mikako Nakano; Takeshi Kobayashi; Takuya Yamashita; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2010-03-10       Impact factor: 2.490

Review 8.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

Review 9.  The design and development of an immunosuppressive drug, mycophenolate mofetil.

Authors:  A C Allison; E M Eugui
Journal:  Springer Semin Immunopathol       Date:  1993

10.  Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.

Authors:  T Furlong; P Martin; M E D Flowers; F Carnevale-Schianca; R Yatscoff; T Chauncey; F R Appelbaum; H J Deeg; K Doney; R Witherspoon; B Storer; K M Sullivan; R Storb; R A Nash
Journal:  Bone Marrow Transplant       Date:  2009-04-20       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.